Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Breast Cancer Metastasis Depends on Expression of Leader Cell Protein

By BiotechDaily International staff writers
Posted on 24 Dec 2013
Image: A breast tumor (blue) uses leader cells (green) to invade muscle tissue (red) in a mouse (Photo courtesy of Dr. Kevin Cheung, Cell).
Image: A breast tumor (blue) uses leader cells (green) to invade muscle tissue (red) in a mouse (Photo courtesy of Dr. Kevin Cheung, Cell).
Cell biologists have identified a protein that they regard as a potential drug target in a unique class of breast cancer cells that lead the process of metastasis into surrounding tissues.

Carcinomas typically migrate into normal tissues as a cohesive multicellular unit, a process termed collective invasion. It has been unclear how different subpopulations of cancer cells contributed to this process.

Investigators at Johns Hopkins University (Baltimore, MD, USA) developed three-dimensional organoid assays to identify the most invasive cancer cells in primary breast tumors. They reported in the December 12, 2013, online edition of the journal Cell that collective invasion was led by specialized cancer cells (leader cells) that were defined by their expression of basal epithelial genes, such as cytokeratin-14 (K14) and p63. Furthermore, examination of human tumor samples showed that K14-expressing cells led collective invasion in the major human breast cancer subtypes.

To confirm the role of K14 in the invasive process, the investigators used gene therapy techniques to block its expression in some tumor lines. Cancer cells with blocked K14 expression and similar but untreated cancer cells were then implanted into different sites on the same mouse. Examination of the resulting tumors showed that leader cells were present in the K14-expressing tumors and were leading vigorous invasions into normal tissue. In the tumors with blocked K14 expression essentially no invasions occurred.

"Metastasis is what most threatens breast cancer patients, and we have found a way to stop the first part of the process in mice," said senior author Dr. Andrew Ewald, assistant professor of cell biology at Johns Hopkins University. "We are still several years away from being able to use these insights to help patients with breast cancer, but we now know which tumor cells are the most dangerous, and we know some of the proteins they rely on to do their dirty work. Just a few leader cells are sufficient to start the process of metastasis, and they require K14 to lead the invasion."

Related Links:

Johns Hopkins University



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.